Simris Alg interim report January - March 2021

INCREASED ACTIVITIES IN NEW BUSINESS VERTICALS, NEW E-COMMERCE PLATFORM LAUNCHED

Simris Alg AB (publ) (FNSE:SIMRIS) has published its financial results for January – March 2021.

• Net sales were 0.492 MSEK (0.265) during the quarter. Net sales in the US were 0.308 MSEK (0.128).
• The operating result was –7.462 MSEK (–6.859).
• Christoffer Tell was appointed CFO.
• Three business verticals were presented - SIMRIS BIOMIMETICS for cosmetics and pharmaceuticals, SIMRIS NOVEL FOODS for new food ingredients, and consumer brand SIMRIS for omega-3 supplements.
• New e-commerce platforms were launched on simris.com for the US market and eu.simris.com for Sweden and the EU.
• EFSA, the EU Food Safety Authority, granted an extension of the deadline to submit requested additional information to Simris Alg's application for authorisation under the Novel Food Regulation. New deadline is September 1, 2021.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

• The company presents a new development plan including new product candidates and upcoming milestones. New board members proposed to the AGM by the nomination committee will strengthen company management to realise the company's potential.
• Simris Alg signs a five-year agreement with Anhalt University of Applied Sciences in Germany (AUAS) for the development of new biologically active substances from microalgae for advanced skincare. The collaboration increases Simris Alg's R&D capacity and aims to accelerate product development within the Simris Biomimetics business vertical.

COMMENT FROM THE CEO: FIRST STEPS IN NEW MARKETS

Those who have followed Simris Alg for a while have surely noticed the significant changes in our business which we implemented during the last quarter. Having successfully developed our platform from lab to industrial scale and taken our first products to market, we have now entered the next phase for real. Here, Simris continues to lead the development of microalgae biotechnology through our new business verticals, in particular Simris Biomimetics. Biologically active ingredients from microalgae for advanced skincare are aimed at a global market worth well over USD 500 billion, meaning we are sitting on a unique gold mine with almost untapped commercial potential. The first quarter also saw a pleasing increase for our e-commerce in the United States, following the launch of our new online store. Continued growth here is important to attract the right partner to operate our US sales of Simris® Algae Omega-3 in the future. Hence, we are excited and look forward to our new board of directors, which will play a key role in realising the potential of Simris moving forward. Spring has arrived! 

The full version of the report is available in Swedish at www.simrisalg.se/investerare

FOR MORE INFORMATION, PLEASE CONTACT:
Fredrika Gullfot, CEO Simris
Tel: +46 761 345 474, email: gullfot@simris.com

ABOUT SIMRIS ALG AB (PUBL)
Simris Alg is a multi-awarded pioneer business developing bioactive substances from algae. The company's purpose and business is to save endagered marine habitats by producing raw materials from microalgae, instead of fish and other marine animals. Simris operates in three business areas: SIMRIS BIOMIMETICS (skincare and pharmaceuticals), SIMRIS NOVEL FOODS (new dietary ingredients), and the SIMRIS consumer brand targeted to the global lifestyle, beauty and wellness markets. Simris Alg's shares are traded on the Nasdaq First North Growth Market with ticker SIMRIS and ISIN SE0008091664. Certified Adviser is Mangold Fondkommission AB, phone +46 (0)8-503 015 50 and email ca@mangold.se.

Tags: